ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
Human Cytomegalovirus (HCMV) Shedding and T-cell Immune Responses in HCMV-seropositive Women During Pregnancy and Postpartum: Prevalence, Natural History, and Risk Factors.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundHuman cytomegalovirus (HCMV) during pregnancy and poor immune control of HCMV are associated with adverse outcomes. Limited data exist on the prevalence, natural history, and risk factors of HCMV shedding and T-cell immune responses during pregnancy and postpartum in HCMV-seropositive women.
methodsSamples from 160 HCMV-seropositive women were collected at 3 time points during pregnancy and once postpartum. Shedding was determined by detecting HCMV DNA in saliva, urine, and vaginal secretions by quantitative polymerase chain reaction. HCMV-specific T-cell immune responses were determined by detecting interferon-gamma released in blood by QuantiFERON-CMV and T-SPOT.CMV assays. Information on demographics and contact with children's bodily fluids was collected.
resultsThe prevalence of HCMV shedding in HCMV-seropositive women in any bodily fluids was 18.8% [95% CI: 13.0-25.7%] during pregnancy and 21.3% [95% CI: 15.2-28.4%] including postpartum. Ethnicity [OR 0.2, 95% CI: 0.05-0.95, P = .043] and gravidity [OR 0.2, 95% CI: 0.05-0.94, P = .042] were associated with detection of shedding. Shedding quantity was associated with contact with children's saliva [Incidence rate ratio 1.98, 95% CI: 1.69-2.33, P < .001]. The prevalence of T-cell immune responses was ≤75% and almost 100% using QuantiFERON-CMV and T-SPOT.CMV, respectively. T-cell immune responses did not correlate with shedding.
conclusionsAround 1 in 5 HCMV-seropositive women shed HCMV during pregnancy and postpartum. Ethnicity and gravidity are associated with shedding, but not T-cell immune responses, and the quantity of shedding is associated with contact with saliva. Further studies investigating HCMV shedding, immune responses and their risk factors in women during pregnancy and postpartum are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.